Overview

* Scynexis Q3 2025 net loss widens to $8.6 mln

* Company receives $24.8 mln one-time payment from GSK, extending cash runway over two years

Outlook

* Scynexis ( SCYX ) expects up to $146 mln in annual net sales milestones from BREXAFEMME relaunch

* Scynexis's ( SCYX ) cash runway extends over two years, supporting SCY-247 development

Result Drivers

* GSK PAYMENT - Scynexis ( SCYX ) received a one-time payment of $24.8 mln from GSK, resolving a disagreement over the Phase 3 MARIO study

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $334,000

Product

Revenue

Q3 Net -$8.59

Income mln

Q3 Basic -$0.17

EPS

Q3 $8.74

Operatin mln

g

Expenses

Q3 -$8.59

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for SCYNEXIS Inc ( SCYX ) is $4.00, about 84.2% above its November 4 closing price of $0.63

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)